Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Psoriasis finds that the continued uptake of Janssen's interleukin 12/23 inhibitor Stelara, which is expected to experience first-line biologic use ahead of the TNF-alpha inhibitors in the second half of the 2012-2022 forecast period, will drive sales growth. Stelara is forecast to achieve sales of $2.2 billion in 2022, accounting for 24 percent of total psoriasis sales. The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab) as well as Pfizer's Janus kinase inhibitor Xeljanz—will also drive sales through 2022. 

The findings also reveal that the TNF-alpha inhibitors, particularly AbbVie/Eisai's Humira, which has displaced Amgen/Stiefel/Pfizer/Takeda's Enbrel as the preferred first-line biologic, will continue to dominate as first-line biologic agents in the first half of our forecast. However, dermatologists will increasingly turn to Stelara for their biologic-naive patients, owing to the drug's favorable risk/benefit profile. This is supported by years of postmarketing safety data and will drive sales in the second half of the 2012-2022 forecast period. Beginning in 2014, the TNF-alpha inhibitors and Stelara will experience competition from emerging biologics and oral agents with novel mechanisms of action. Although concerns about their undefined safety profiles will restrict uptake initially, the emerging IL-17 inhibitors, Xeljanz, and Merck's IL-23 inhibitor MK-3222, will increase competition within the TNF-alpha-refractory space. Celgene's oral phosphodiesterase-4 inhibitor apremilast—which is also poised to enter the market in 2014—may see use in earlier lines of therapy than the emerging biologics and Xeljanz.

"Of the emerging systemic agents, the three IL-17 inhibitors—secukinumab, ixekizumab, and brodalumab—as well as MK-3222, have shown the most impressive efficacy. The efficacy of ixekizumab and brodalumab in Phase II clinical trials appears comparable to the most effective biologic for psoriasis, Janssen/Merck/Mitsubishi Tanabe's Remicade, and Phase III clinical trial data for secukinumab suggests impressive efficacy comparable to the two other agents in this drug class," said Decision Resources Business Insights Analyst Kathryn Beane. "Nevertheless, reservations about these agents' novel mechanisms of action and relatively limited safety profiles will mean that physicians will reserve these drugs initially for patients who have failed TNF-alpha inhibitors and Stelara."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  This report analyzes the worldwide markets for Chiral ... Products: Intermediates, Analytical, and Others. The End Use ... Agrochemicals. The report provides separate comprehensive analytics for the ... , and Rest of World. Annual estimates and ... Also, a six-year historic analysis is provided for these ...
(Date:2/24/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Urinary Incontinence Drugs Price ... in the global Urinary Incontinence market. The research answers the ... drugs marketed for Urinary Incontinence and their clinical attributes? How are ...
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: ... markets innovative proprietary products for the urology market, will ... year ended December 31, 2016 before the market open ... Company will host a conference call and webcast to ... March 9, 2017 at 11:00 a.m. Eastern Time (10:00 ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. ... Not to Hot,” which will begin airing on February 24, 2017. The show chronicles ... the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
Breaking Medicine News(10 mins):